Cerebrolysin dosing reference
Common vial sizes, typical dose ranges, and a free reconstitution calculator pre-configured for Cerebrolysin. Not medical advice. Always verify against your vial label and your provider's protocol.
Cerebrolysin reconstitution
Pre-loaded with common Cerebrolysin values — adjust to your vial.
Inputs
Cerebrolysin common vial sizes: 10 mg, 30 mg. Typical dose range: 5–30 mg. Clinical literature. Typically IV/IM. Not medical advice.
for a 5 mg dose
- Concentration
- 10.0 mg/ml
- Volume
- 0.500 ml
- Per ml
- 100 u
Not medical advice. Always verify against your vial label and your provider's instructions. Re-check before drawing.
About Cerebrolysin
Nootropic peptides modulate neurotransmitter systems — semax (BDNF/melanocortin), selank (GABAergic), cerebrolysin (neurotrophic), dihexa (synaptogenic). They are studied for focus, mood, and cognitive recovery.
How it's used
Subcutaneous, intranasal, or oral delivery depending on the compound. Cycles tend to be short (2–6 weeks) with breaks between to reset receptor sensitivity.
Storage
Refrigerate reconstituted vials. Intranasal sprays should be kept cool and used within manufacturer-specified windows.
Watch for
- Headache or sleep disruption in the first days
- Mood shifts — both positive and negative
- Limited rigorous human trials for most compounds
Protocols using Cerebrolysin
Cerebrolysin vs other Nootropic peptides
5 compounds comparedReference dose ranges for the nootropic category. Tap any compound to open its full reference page.
| Compound | Brand names | Typical dose | Vial sizes | Status |
|---|---|---|---|---|
| Cerebrolysin | — | 5–30 mg | 10, 30 mg | Research |
| Semax | — | 0.2–0.4 mg | 5, 10 mg | Research |
| Selank | — | 0.3–0.9 mg | 5, 10 mg | Research |
| Dihexa | — | 8–45 mg | 10, 25 mg | Research |
| P21 | — | 1–2 mg | 2, 5 mg | Research |
Dose ranges summarized from FDA-approved labels (for approved compounds) and peer-reviewed research (for the rest). See the resources page for source databases.
Cerebrolysin FAQ
Answers, not hype.
Cerebrolysin is a peptide in the Nootropic category. It is a research peptide and is not FDA-approved for human use. The dose ranges shown (5–30 mg) are summarized from peer-reviewed research literature where evidence is preliminary.
Cerebrolysin most commonly ships in 10, 30 mg vials. Typical reconstitution volumes are 1, 2 ml of bacteriostatic water — choose the volume to land on a syringe-friendly unit count for your target dose.
Use the formula concentration = vial mg ÷ BAC water ml, then volume = dose mg ÷ concentration, then units = volume × 100 (for U-100). For example, a 10 mg vial reconstituted with 1 ml gives 10.00 mg/ml — at the typical low dose of 5 mg that resolves to 50.0 units. The free reconstitution calculator on this site verifies the math against your specific vial.
No. Cerebrolysin is a research peptide and is not FDA-approved for human use in the United States as of April 2026. Any use must come through a licensed healthcare provider, typically via a compounding pharmacy.
Side-effect profiles for research peptides are characterized in published research rather than an FDA label. Most users report mild local reactions at the injection site, occasional fatigue, and headache in the first few doses. Long-term human safety data is limited for most research compounds. Discuss with your prescribing provider before starting.
No. The values shown are reference numbers summarized from authoritative sources — FDA-approved labels for approved compounds and peer-reviewed research for the rest. They are not personalized recommendations. Always follow your prescribing provider's instructions and verify every calculation against your vial label.
References & sources
Research peptideCerebrolysin is a research peptide. It is not FDA-approved for human use. The ranges shown above are summarized from peer-reviewed clinical and pre-clinical literature, where evidence remains preliminary. Discuss any use with a licensed healthcare provider.
- PubMed research literaturePeer-reviewed research on Cerebrolysin. Evidence is preliminary; Cerebrolysin is not FDA-approved for human use.
- ClinicalTrials.govNIH database of registered clinical trials involving Cerebrolysin, completed or in progress.
See the resources page for the full list of databases this site cross-checks against.
Track Cerebrolysin in the app
History, reminders, body-map injection rotation, Apple Watch logging, and a doctor-ready PDF — all bundled with the calculator.
Download on theApp Store